Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 3/20 | 0.46 |
| ▸ | TMPRSS15 | P98073 | 3/20 | 0.46 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.44 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | CPA3 | P15088 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21577937 | 0.88 | HDAC1 (0.48) | PRSS1TMPRSS15SLC7A5CA12CA1 | |
| SCHEMBL21578138 | 0.84 | SLC7A5 (0.64) | PRSS1TMPRSS15CYSLTR2CYSLTR1SLC7A5 | |
| SCHEMBL20168730 | 0.84 | CPA3 (0.46) | PRSS1TMPRSS15SLC7A5NPSR1CA12 | |
| SCHEMBL15828913 | 0.84 | SLC7A5 (0.47) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL3790673 | 0.82 | NR1H4 (0.51) | NPSR1CA12CA1CA2CA9 | |
| SCHEMBL21577928 | 0.82 | HTT (0.56) | PRSS1TMPRSS15CYSLTR2CYSLTR1CA12 | |
| SCHEMBL21577939 | 0.81 | SLC7A5 (0.40) | PRSS1TMPRSS15SLC7A5CA12CA1 | |
| SCHEMBL21578054 | 0.81 | SLC7A5 (0.39) | SLC7A5CA12CA1CA2CA9 | |
| SCHEMBL21578143 | 0.80 | SLC7A5 (0.56) | PRSS1TMPRSS15CYSLTR2CYSLTR1SLC7A5 | |
| SCHEMBL26427155 | 0.80 | ADRB2 (0.36) | PRSS1TMPRSS15SLC7A5NPSR1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2023-04-27 | — | — | US | disclosed |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY AS CR V.V.I. (CZ) | 2021-11-18 | — | — | US | disclosed |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | THE JOHNS HOPKINS UNIVERSITY | 2019-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190352255-A1 | NOVEL PRODRUG COMPOSITIONS AND UTILITY OF HYDROXAMATE-BASED GCPII INHIBITORS | GPI, TPI1, HPGDS | PRSS1 526/4885TMPRSS15 179/4885CYSLTR2 1976/4885 |
| US-20210355079-A1 | PRODRUGS OF HYDROXAMATE-BASED GCPII INHIBITORS | TPI1, HPGDS, GPI | PRSS1 589/4885TMPRSS15 202/4885CYSLTR2 2061/4885 |
| US-20230128984-A1 | BILE ACID-GCPII INHIBITOR CONJUGATES TO TREAT INFLAMMATORY DISEASES, INCLUDING INFLAMMATORY BOWEL DISEASE (IBD) | SLC10A2, GPBAR1, NR1H4 | PRSS1 2096/4885TMPRSS15 1117/4885CYSLTR2 662/4885 |
| US-11059775-B2 | Prodrug compositions and utility of hydroxamate-based GCPII inhibitors | GLS, HPGDS, GPI | PRSS1 694/4885TMPRSS15 208/4885CYSLTR2 2293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.